NCT06270706 - A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 30, 2023

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Metastatic Solid Tumor

Interventions

DRUG

PLN-101095

DRUG

Pembrolizumab

Trial Locations (5)

RECRUITING

NEXT Virginia, Fairfax

RECRUITING

South Texas Accelerated Research Therapeutics (START), Grand Rapids

RECRUITING

University of Texas MD Anderson Cancer Center, Houston

RECRUITING

NEXT Austin, Austin

RECRUITING

Yale University, New Haven